These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 22152401)
1. Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial. Barber JP; Barrett MS; Gallop R; Rynn MA; Rickels K J Clin Psychiatry; 2012 Jan; 73(1):66-73. PubMed ID: 22152401 [TBL] [Abstract][Full Text] [Related]
2. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901 [TBL] [Abstract][Full Text] [Related]
3. The effect of sertraline add-on to brief dynamic psychotherapy for the treatment of postpartum depression: a randomized, double-blind, placebo-controlled study. Bloch M; Meiboom H; Lorberblatt M; Bluvstein I; Aharonov I; Schreiber S J Clin Psychiatry; 2012 Feb; 73(2):235-41. PubMed ID: 22401479 [TBL] [Abstract][Full Text] [Related]
4. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382 [TBL] [Abstract][Full Text] [Related]
5. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. Lin CH; Lin SH; Jang FL J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699 [TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725 [TBL] [Abstract][Full Text] [Related]
7. Journal Watch review of Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial. Jain S J Am Psychoanal Assoc; 2014 Feb; 62(1):113-5. PubMed ID: 24610762 [No Abstract] [Full Text] [Related]
8. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613 [TBL] [Abstract][Full Text] [Related]
10. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941 [TBL] [Abstract][Full Text] [Related]
11. Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. van Calker D; Zobel I; Dykierek P; Deimel CM; Kech S; Lieb K; Berger M; Schramm E J Affect Disord; 2009 Apr; 114(1-3):243-53. PubMed ID: 18849079 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients. Iwata N; Tourian KA; Hwang E; Mele L; Vialet C J Psychiatr Pract; 2013 Jan; 19(1):5-14. PubMed ID: 23334675 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. Clayton AH; Kornstein SG; Dunlop BW; Focht K; Musgnung J; Ramey T; Bao W; Ninan PT J Clin Psychiatry; 2013 Oct; 74(10):1010-7. PubMed ID: 24229754 [TBL] [Abstract][Full Text] [Related]
14. Combination of pharmacotherapy with electroconvulsive therapy in prevention of depressive relapse: a pilot controlled trial. Yildiz A; Mantar A; Simsek S; Onur E; Gökmen N; Fidaner H J ECT; 2010 Jun; 26(2):104-10. PubMed ID: 19935091 [TBL] [Abstract][Full Text] [Related]
15. Questions raised by the failure of a trial of short-term psychodynamic therapy versus pharmacotherapy for major depressive disorder. Kocsis JH J Clin Psychiatry; 2012 Jan; 73(1):64-5. PubMed ID: 22316577 [No Abstract] [Full Text] [Related]
16. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. Khin NA; Chen YF; Yang Y; Yang P; Laughren TP J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123 [TBL] [Abstract][Full Text] [Related]
17. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. Dunlop BW; Reddy S; Yang L; Lubaczewski S; Focht K; Guico-Pabia CJ J Clin Psychopharmacol; 2011 Oct; 31(5):569-76. PubMed ID: 21869698 [TBL] [Abstract][Full Text] [Related]
18. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo. Kornstein SG; Fava M; Jiang Q; Tourian KA Psychopharmacol Bull; 2009; 42(3):21-35. PubMed ID: 19752839 [TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552 [TBL] [Abstract][Full Text] [Related]
20. Comparison of venlafaxine alone versus venlafaxine plus bright light therapy combination for severe major depressive disorder. Güzel Özdemir P; Boysan M; Smolensky MH; Selvi Y; Aydin A; Yilmaz E J Clin Psychiatry; 2015 May; 76(5):e645-54. PubMed ID: 26035199 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]